S. Leonard

发表

Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15

L. Turka, T. Wickham, Enping Hong, 2021, Cancer Immunology, Immunotherapy.

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer

B. Hendriks, J. Fitzgerald, P. Bunn, 2017, Anti-cancer drugs.

64 Cu-MM-302 Positron Emission Tomography Quanti ﬁ es Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

B. Hendriks, A. Shields, P. LoRusso, 2017 .

Multiscale Kinetic Modeling of Liposomal Doxorubicin Delivery Quantifies the Role of Tumor and Drug-Specific Parameters in Local Delivery to Tumors

U. Nielsen, B. Hendriks, Helen Lee, 2012, CPT: pharmacometrics & systems pharmacology.

HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.

U. Nielsen, B. Hendriks, P. Zandstra, 2012, Toxicology and applied pharmacology.

Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.

B. Hendriks, T. Wickham, E. Geretti, 2016, Cancer research.

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

Karen Campbell, Ian Krop, Barry A Siegel, 2017, Clinical Cancer Research.

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

U. Nielsen, B. Hendriks, D. Jaffray, 2015, Molecular Cancer Therapeutics.

A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography.

B. Hendriks, D. Jaffray, J. Hoppin, 2015, Nanomedicine : nanotechnology, biology, and medicine.

Deposition characteristics and resulting DNA damage patterns of liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts.

B. Hendriks, J. Fitzgerald, Helen Lee, 2018 .

Abstract 3637: MM-302, a HER2-targeted liposomal doxorubicin, shows binding/uptake and efficacy in HER2 2+ cells and xenograft models

B. Hendriks, Helen Lee, T. Wickham, 2011 .

Abstract P3-14-09: Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines

C. Benz, B. Hendriks, John W. Park, 2010 .